Placental growth factor level in blood and urine in the first half of pregnancy: cross-sectional study
DOI:
https://doi.org/10.37800/RM.4.2023.23-30Keywords:
pregnancy, first trimester, second trimester, placental growth factor, PLGF, blood, urineAbstract
Relevance: Assessment of the level of placental growth factor (PLGF) both in blood serum and in urine can be useful for evaluating reference values for developing rapid test systems for assessing the level of PLGF associated with pregnancy complications.
The study aimed to assess levels of placental growth factor (PLGF) in blood and urine in the first half (≤20 weeks) of pregnancy in low-risk pregnant women and the relationship between these indicators.
Materials and Methods: A multicenter cross-sectional study was conducted. The study included 555 women at low risk of complications at 4-20 weeks of pregnancy. All the subjects underwent a general clinical examination assessment of previous health events. The gestation period was determined by the date of the last menstruation and by ultrasound fetometry. PLGF concentrations in blood and urine were determined by enzyme immunoassay.
Results: Concentrations of PLGF in the blood in the first trimester (4-13 weeks) of pregnancy in the subjects amounted to 29.8 (17.9-45.6) pg/ml and was higher than the level of PLGF in urine 22.7 (13.9-39.4) pg/ml (p<0.001). In the second trimester of pregnancy, there were no significant differences in the levels of PLGF in blood and urine (p=0.207), the average concentration of which was 28.8 (19.1-48.1) pg/ml and 33.7 (19.8-47.4) pg/ml, respectively. Evaluating the correlation between serum and urinary PLGF levels revealed a moderate positive relationship (r = 0.403) throughout the entire first half of pregnancy and when ranking data for the first (r = 0.411) and second (r = 0.406) trimesters of pregnancy. No correlation was found between the gestation period and the concentration of serum and urinary PLGF.
Conclusion: The average concentration of PLGF in blood and urine in the first trimester of pregnancy is 29.8 (17.9-45.6) pg/ml and 22.7 (13.9-39.4) pg/ml, respectively. In the second trimester of pregnancy, the concentration of PLGF in blood and urine was 28.8 (19.1-48.1) pg/ml and 33.7 (19.8-47.4) pg/ml, respectively. In the first half of pregnancy, PLGF levels in blood and urine do not significantly change their concentration. The concentration of PLGF in urine has a moderate positive correlation with the concentration of PLGF in the blood.
References
Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens. 2017;31(12):782-786.
https://doi.org/10.1038/jhh.2017.61
Newell LF, Holtan SG. Placental growth factor: What hematologists need to know? Blood Rev. 2017;31(1):57-62.
https://doi.org/10.1016/j.blre.2016.08.004
Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K, Del Vecchio S, Lei KJ, Chou JY, Persico MG. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene on chromosome 14. Oncogene. 1993;8(4):925-931.
https://pubmed.ncbi.nlm.nih.gov/7681160/
Arad A, Nammouz S, Nov Y, Ohel G, Bejar J, Vadasz Z. The Expression of Neuropilin-1 in Human Placentas from Normal and Pre-eclamptic Pregnancies. Int J Gynecol Pathol. 2017;36(1):42-49.
https://doi.org/10.1097/PGP.0000000000000283
Jauniaux E, Hempstock J, Greenwold N, Burton GJ. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal placental blood flow in normal and abnormal early pregnancies. Am J Pathol. 2003;162(1):115-125.
https://doi.org/10.1016/S0002-9440(10)63803-5
Тусупбекова М.М., Стабаева Л.М., Мухаммад И., Усеева М.С., Шарафутдинова К.Н., Бисембаев Т.Б. Плацента как важный компонент медико-биологической системы «мать-плацента-плод»: обзор литературы. Репрод. Мед. 2023;3(56):72-79.
Tusupbekova MM, Stabaeva LM, Mukhammad I, Useeva MS, Sharafutdinova KN, Bisembaev TB. The placenta as an important component of the medical and biological system “mother-placenta-fetus”: a review of the literature. Reprod. Med. 2023;3(56):72-79. (In Russ.).
https://doi.org/10.37800/RM.3.2023.72-79
Иceнoвa С.Ш., Бодыков Г.Ж., Шукирбаева А.С., Кубесова М.О., Зият Л., Сапаралиева А.М., Исина Г.М. Состояние фетоплацентарного комплекса у пациенток после применения ВРТ. Репрод. Мед. 2020;1(42):1-3.
Isenova SSh, Bodykov GZh, Shukirbaeva AS, Kubesova MO, Zijat L, Saparalieva AM, Isina GM. The state of the fetoplacental complex in patients after ART. Reprod. Med. 2020;1(42):1-3. (In Russ.).
https://doi.org/10.37800/rm2020-1-3
Ahmed A., Perkins J. Angiogenesis and intrauterine growth restriction. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14(6):981-998.
https://doi.org/10.1053/beog.2000.0139
Wa Law L, Sahota DS, Chan LW, Chen M, Lau TK, Leung TY. Serum placental growth factor and fms-like tyrosine kinase 1 during first trimester in Chinese women with pre-eclampsia--a case-control study. J Matern Fetal Neonatal Med. 2011;24(6):808-811.
https://doi.org/10.3109/14767058.2010.531309
Stepan H, Hund M, Andraczek T. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome. Hypertension. 2020;75(4):918-926.
https://doi.org/10.1161/HYPERTENSIONAHA.119.13763
Friedman AM., Cleary KL. Prediction and prevention of ischemic placental disease. Semin Perinatol. 2014;38(3):177-182.
https://doi.org/10.1053/j.semperi.2014.03.002
Pillai RN, Konje JC, Tincello DG, Potdar N. Role of serum biomarkers in the prediction of outcome in women with threatened miscarriage: a systematic review and diagnostic accuracy meta-analysis. Hum Reprod Upd. 2016;22(2):228-239.
https://doi.org/10.1093/humupd/dmv054
Trottmann F, Baumann M, Amylidi-Mohr S, Surbek D, Risch L, Mosimann B, Raio L. Angiogenic profiling in HELLP syndrome cases with or without hypertension and proteinuria. Eur J Obstet Gynecol Reprod Biol. 2019;243:93-96.
https://doi.org/10.1016/j.ejogrb.2019.10.021
Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63(2):346-352.
https://doi.org/10.1161/HYPERTENSIONAHA.113.01787
Thomas-Schoemann A, Blanchet B, Boudou-Rouquette P, Golmard JL, Noe G, Chenevier-Gobeaux C, Lebbe C, Pages C, Durand JP, Alexandre J. Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?) J Clin Pharmacol. 2015;55(4):478-479.
https://doi.org/10.1002/jcph.429
Chaemsaithong P, Sahota D, Pooh RK, Zheng M, Ma R, Chaiyasit N, Koide K, Shaw SW, Seshadri S, Choolani M. First-trimester pre-eclampsia biomarker profiles in Asian population: multicenter cohort study. Ultrasound Obstet Gynecol. 2020;56(2):206-214.
https://doi.org/10.1002/uog.21905
Тусупкалиев А., Гайдай А., Бермагамбетова С., Жумагулова С., Аренова Ш., Калдыгулова Л., Динец А. Концентрация плацентарного фактора роста в крови и моче у беременных низкого риска казахской популяции в первом триместре беременности: поперечное исследование. West Kaz Med J. 2020;2(62):185-191.
Tusupkaliyev A, Gajday A, Bermagambetova S, Zhumagulova S, Arenova Sh, Kaldygulova L, Dinets A. Concentration of placental growth factor in blood and urine in low-risk pregnant women of the Kazakh population in the first trimester of pregnancy: a cross-sectional study. West Kaz Med J. 2020;2(62):185-191. (In Russ.).
Holness N. High-Risk Pregnancy. Nurs Clin North Am. 2018. – Vol. 53(2). – P. 241-251.
https://doi.org/10.1016/j.cnur.2018.01.010
Lawson GW. Naegele's rule and the length of pregnancy – A review. Aust NZJ Obstet Gynaecol. 2021;61(2):177-182.
https://doi.org/10.1111/ajo.13253
Mei JY, Afshar Y, Platt LD. First-Trimester Ultrasound. Obstet Gynecol Clin North Am. 2019;46(4):829-852.
https://doi.org/10.1016/j.ogc.2019.07.011
Dinets A, Pernemalm M, Kjellin H, Sviatoha V, Sofiadis A, Juhlin CC, Zedenius J, Larsson C, Lehtio J, Hoog A. Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions. PLoS One. 2015;10(5):e0126472.
https://doi.org/10.1371/journal.pone.0126472
Lim S, Li W, Kemper J, Nguyen A, Mol BW, Reddy M. Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis. Obstet Gynecol. 2021;137(1):72-81.
https://doi.org/10.1097/AOG.0000000000004149
Agrawal S, Shinar S, Cerdeira AS, Redman C, Vatish M. Predictive Performance of PlGF (Placental Growth Factor) for Screening Preeclampsia in Asymptomatic Women: A Systematic Review and Meta-Analysis. Hypertension. 2019;74(5):1124-1135.
https://doi.org/10.1161/HYPERTENSIONAHA.119.13360
Chen W, Wei Q, Liang Q, Song S, Li J. Diagnostic capacity of sFlt-1/PlGF ratio in fetal growth restriction: A systematic review and meta-analysis. Placenta. 2022;127:37-42.
https://doi.org/10.1016/j.placenta.2022.07.020
Meiramova A, Smagulova A, Akhetova N, Ukybasova T, Ainabekova B. Placental growth factor and maternal characteristics in the first trimester among pregnant women of Kazakh nationality. Georgian Med News. 2018;279:29-33.
https://pubmed.ncbi.nlm.nih.gov/30035718/
Zhang J, Han L, Li W, Chen Q, Lei J, Long M, Yang W, Li W, Zeng L, Zeng S. Early prediction of preeclampsia and small-for-gestational-age via multi-marker model in Chinese pregnancies: a prospective screening study. BMC Pregnancy Childbirth. 2019;19(1):304.
https://doi.org/10.1186/s12884-019-2455-8
Ng QJ, Han JY, Saffari SE, Yeo GS, Chern B, Tan KH. Longitudinal circulating placental growth factor (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1) concentrations during pregnancy in Asian women: a prospective cohort study. BMJ Open. 2019;9(5):e028321.
https://doi.org/10.1136/bmjopen-2018-028321
Saffer C, Olson G, Boggess KA, Beyerlein R, Eubank C, Sibai BM, Group NS. Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia. Pregnancy Hypertens. 2013;3(2):124-132.
https://doi.org/10.1016/j.preghy.2013.01.004
Widmer M, Cuesta C, Khan KS, Conde-Agudelo A, Carroli G, Fusey S, Karumanchi SA, Lapaire O, Lumbiganon P, Sequeira E, Zavaleta N, Frusca T, Gülmezoglu AM, Lindheimer MD. Accuracy of angiogenic biomarkers at ≤20 weeks' gestation in predicting the risk of pre-eclampsia: A WHO multicentre study. Pregnancy Hypertens. 2015;5(4):330-338.
https://doi.org/10.1016/j.preghy.2015.09.004
Savvidou MD, Akolekar R, Zaragoza E, Poon LC, Nicolaides KH. First trimester urinary placental growth factor and development of pre-eclampsia. BJOG. 2009;116(5):643-647.
https://doi.org/10.1111/j.1471-0528.2008.02074.x
Hebert-Schuster M, Ranaweera T, Fraichard C, Gaudet-Chardonnet A, Tsatsaris V, Guibourdenche J, Lecarpentier E. Urinary sFlt-1 and PlGF levels are strongly correlated to serum sFlt-1/PlGF ratio and serum PlGF in women with preeclampsia. Pregnancy Hypertens. 2018;12:82-83.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The rights to a manuscript accepted for publication are transferred to the Journal Publisher. When reprinting all or part of the material, the author must refer to the primary publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The articles published in this Journal are licensed under the CC BY-NC-ND 4.0 (Creative Commons Attribution – Non-Commercial – No Derivatives 4.0 International) license, which provides for their non-commercial use only. Under this license, users have the right to copy and distribute the material in copyright but are not permitted to modify or use it for commercial purposes. Full details on the licensing are available at https://creativecommons.org/licenses/by-nc-nd/4.0/.
